Isconova has partnership agreements with three different companies and one world leading institute in the human vaccines market. In the veterinary market Isconova has partnership agreements with three vaccine companies that market products with Isconova adjuvants and partnership agreements with two other vaccine companies with products in clinical development. In addition Isconova has a number of MTAs in human- and veterinary vaccines and is also involved in several EU projects. Are you interested in finding out how Isconova can contribute to your vaccine development projects, please contact us.
Our partners
|
www.genocea.com
|
The American research and development company
Genocea Biosciences has received great attention for
their progress in vaccine development. The company
was founded in 2006 in Cambridge, USA, and was named “One of the World’s Most Intriguing Startups” in 2009 by Businessweek. Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity.
Isconovas cooperation with Genocea Biosciences includes the use of Isconovas Matrix-M™ in vaccines under development against 8 different infectious disease targets, including herpes simplex type-2, Chlamydia trachomatis, Streptococcus pneumoniae, malaria and gonorrhea.
|
|
www.jenner.ac.uk
|
Headquartered at Oxford University’s medical school campus the Jenner Institute is a collaboration between the University and the UK Institute for Animal Health. The Institute, regarded as world-leading in vaccinology, was founded in 2005 to develop innovative vaccines against major global diseases.
Isconovas cooperation with Jenner Institute includes the use of Isconovas Matrix-M™ in a malaria vaccine under development.
|
|
www.crucell.com
www.jnj.com
|
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Crucell focuses on the research & development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases.
The license agreement with Crucell includes the use of Isconova's Matrix-M™ adjuvant in influenza, HIV and malaria vaccines.
|
|
www.intervacc.com
|
Intervacc AB is a Swedish biotech company in the frontline of vaccine development. The research is focused on the new generation of recombinant vaccines within animal health. The company has after many years of research almost finalized the development of a safe and efficacious vaccine Strangvac® against the highly contagious disease strangles in horses caused by Streptococcus equi. Research has also been initiated aiming at developing recombinant vaccines against Streptococcus zooepidemicus, another most important infectious agent in horses.
Intervacc has an agreement with Isconova to use the Matrix-technology in its strangles vaccine.
|
|
www.pharmaq.com
|
PHARMAQ is a world leading pharmaceutical company specializing in aquaculture. The main products are vaccines for farmed fish and since establishment 14 fish vaccines have been developed and introduced to different markets. The headquarters are based in Oslo and Overhalla, both in Norway.
Isconova and Pharmaq are collaborating in the establishment of a new, innovative generation of fish vaccines
|
|
www.merck-animal-health.com
|
Merck Animal Health, knon as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck.
Isconova supplies Merck Animal Health with Matrix-C™ for the equine influenza vaccine Equilis®Prequenza. The vaccine was launched in 2006 and Isconova has since produced millions of doses of Matrix-C™ for Equilis®Prequenza, which has become a leading equine influenza vaccine in Europe.
|
|
|
VetBioChem (NPO Narvac) is a leading animal health company in Russia. VetBioChem produces vaccines, diagnostics and therapeutics for cattle, pigs and companion animals.
Since 2010 Isconova and VetBioChem have collaborated on the development of rabies vaccines for dogs and cats. These vaccines, Rabix and Rabifel, were launched February 2012 and are the first marketed veterinary vaccines using Isconova’s adjuvant Matrix-M™Vet.
The agreement with VetBioChem includes revenues for Isconova for the supply of Matrix-M™Vet as well as royalties based on future sales of the rabies vaccines.
|
External funded R&D projects ongoing
Improved vaccines against intracellular pathogens in aquaculture
Partner: Pharmaq
The project is funded by Eurostars - E!5934 New-Vac.
Read more at:
http://www.eurostars-eureka.eu/
West Nile Shield Project: Epidemiology, Diagnosis and Prevention of West Nile Virus in Europe
The project is funded by Wings - Grant Agreement No. 261426
Read more at:
www.west-nile-shield-project.eu
Vaccines against helminth infections
The project is funded by Paravac - Grant Agreement No. 265862
Read more at:
www.paravac.eu/index.php?page=partners
